Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
Authors: Francesco Atzori, Josep Tabernero, Andrés Cervantes, Ludmila Prudkin, Jordi Andreu, Edith Rodríguez-Braun, Amparo Domingo, Jorge Guijarro, Cristina Gamez, Jordi Rodon, Serena Di Cosimo, Holly Brown, Jason Clark, James S. Hardwick, Robert A. Beckman, William D. Hanley, Karl Hsu, Emiliano Calvo, Susana Roselló, Ronald B. Langdon, José Baselga
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361881046